|
|
Volumn 64, Issue , 2013, Pages 2-7
|
|
New drug development for cognitive enhancement in mental health: Challenges and opportunities
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOSERINE;
DONEPEZIL;
MEMANTINE;
METABOTROPIC RECEPTOR AGONIST;
NEUMENDAL;
NEUROLEPTIC AGENT;
NOOTROPIC AGENT;
UNCLASSIFIED DRUG;
ALZHEIMER DISEASE;
ATTENTION DEFICIT DISORDER;
COGNITION;
COGNITIVE DEFECT;
COGNITIVE THERAPY;
DELUSION;
DEMENTIA;
DISEASE COURSE;
DRUG MECHANISM;
DRUG TARGETING;
HALLUCINATION;
HUMAN;
LANGUAGE DISABILITY;
MEMORY DISORDER;
MENTAL HEALTH;
NEUROMODULATION;
NOTE;
PHOBIA;
PRIORITY JOURNAL;
PSYCHOSIS;
PUBLIC HEALTH;
SCHIZOPHRENIA;
SYNAPTIC TRANSMISSION;
ANIMALS;
COGNITION;
COGNITION DISORDERS;
DRUG DISCOVERY;
HUMANS;
MENTAL DISORDERS;
NEUROPHARMACOLOGY;
NEUROPSYCHIATRY;
NOOTROPIC AGENTS;
PERFORMANCE-ENHANCING SUBSTANCES;
|
|
EID: 84866431339
PISSN: 00283908
EISSN: 18737064
Source Type: Journal
DOI: 10.1016/j.neuropharm.2012.07.041 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|